{"answer":{"query":"Trijardy XR","resolved_as":"applications","packages":8,"applications":["NDA212614"],"identity":{"application_numbers":["NDA212614"],"marketing_categories":["NDA"],"labelers":[],"dosage_forms":[{"text":"TABLET, EXTENDED RELEASE","untrusted":true}],"marketing_start":{"earliest":"2020-04-23","latest":"2020-04-23","packages_with_a_start_date":8}},"generic_entry":[{"application":"NDA212614","date":"2037-12-08","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12364700*PED","productNo":"001"},"latest_patent_expiry":"2037-12-08","latest_exclusivity_expiry":"NOT_PROVIDED","dated_barriers":111,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":17,"exclusivities_listed":0,"fact_id":"df2664c78e85402d3067a344"}],"label_history":{"events_total":7,"non_cmc_events":7,"counts_by_class":{"LABELING":6,"EFFICACY":1},"cmc_events":0,"recent_non_cmc_events":[{"application":"NDA212614","submission_no":32,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2026-08-11","documents":[{"type":"Letter","date":"2026-08-14","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/201281Orig1s043;206111Orig1s050;208026Orig1s034;208658Orig1s038;212614Orig1s032ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-08-18","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212614s032lbl.pdf","untrusted":true}}],"fact_id":"3720c00e60bc9c26b58eaf11"},{"application":"NDA212614","submission_no":29,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-24","documents":[{"type":"Label","date":"2025-10-27","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212614s029lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-10-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/204629Orig1s063,206111Orig1s046,208658Orig1s034,206073Orig1s044,212614Orig1s029ltr.pdf","untrusted":true}}],"fact_id":"685c5613372d4fce96e1f914"},{"application":"NDA212614","submission_no":20,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2023-10-30","documents":[{"type":"Label","date":"2023-10-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212614s020lbl.pdf","untrusted":true}},{"type":"Letter","date":"2023-10-31","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/206073Orig1s036; 206111Orig1s042; 208658Orig1s028; 212614Orig1s020ltr.pdf","untrusted":true}}],"fact_id":"977072eec3870c3e6925365f"},{"application":"NDA212614","submission_no":16,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2022-10-13","documents":[{"type":"Letter","date":"2022-10-14","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/212614Orig1s016ltr.pdf","untrusted":true}},{"type":"Label","date":"2022-10-28","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212614s016lbl.pdf","untrusted":true}}],"fact_id":"603a1defbc3ae9ba6435466d"},{"application":"NDA212614","submission_no":10,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2021-06-11","documents":[{"type":"Label","date":"2021-06-14","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212614s008s010lbl.pdf","untrusted":true}},{"type":"Letter","date":"2021-06-15","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204629Orig1s028, s029; 206073Orig1s027, s030; 206111Orig1s025, s026; 208658Orig1s013, s015; 212614Orig1s008, s010ltr.pdf","untrusted":true}}],"fact_id":"0d9a6c7f8a7d290b64ba2cac"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":4,"te_code_counts":{"NOT_PROVIDED":4},"marketing_status_counts":{"Prescription":4},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA212614","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRIJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"25MG;5MG;1GM","untrusted":true}},{"application":"NDA212614","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRIJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"10MG;5MG;1GM","untrusted":true}},{"application":"NDA212614","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRIJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"5MG;2.5MG;1GM","untrusted":true}},{"application":"NDA212614","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"TRIJARDY XR","untrusted":true},"form":{"text":"TABLET, EXTENDED RELEASE;ORAL","untrusted":true},"strength":{"text":"12.5MG;2.5MG;1GM","untrusted":true}}]},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"EMPAGLIFLOZIN","untrusted":true},"recruiting_interventional_count":94,"not_yet_recruiting_count":29,"by_phase":{"PHASE1/PHASE2":4,"PHASE3":18,"PHASE1":7,"PHASE4":29,"PHASE2":18,"EARLY_PHASE1":8,"NA":6,"PHASE2/PHASE3":4},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT03424005","title":{"text":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Hoffmann-La Roche","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2018-03-30","link":{"text":"https://clinicaltrials.gov/study/NCT03424005","untrusted":true}},{"nct_id":"NCT05972564","title":{"text":"The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Vanderbilt University Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2023-09-06","link":{"text":"https://clinicaltrials.gov/study/NCT05972564","untrusted":true}},{"nct_id":"NCT07038356","title":{"text":"Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Christian Schulze","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-12-08","link":{"text":"https://clinicaltrials.gov/study/NCT07038356","untrusted":true}},{"nct_id":"NCT07845630","title":{"text":"A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Boehringer Ingelheim","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-29","start_date":"2026-10-14","link":{"text":"https://clinicaltrials.gov/study/NCT07845630","untrusted":true}},{"nct_id":"NCT06249932","title":{"text":"Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"National Taiwan University Hospital","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-28","start_date":"2024-03-13","link":{"text":"https://clinicaltrials.gov/study/NCT06249932","untrusted":true}}],"fact_id":"ab0e426b6d1a73f39080ec45"},{"ingredient":{"text":"LINAGLIPTIN","untrusted":true},"recruiting_interventional_count":6,"not_yet_recruiting_count":6,"by_phase":{"PHASE4":4,"PHASE3":1,"NA":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06862739","title":{"text":"Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Nabiqasim Industries (Pvt) Ltd","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-04-17","start_date":"2025-10-30","link":{"text":"https://clinicaltrials.gov/study/NCT06862739","untrusted":true}},{"nct_id":"NCT07442006","title":{"text":"Glycemic Variability of Combination Therapies in T2DM","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"JW Pharmaceutical","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-03-02","start_date":"2025-10-29","link":{"text":"https://clinicaltrials.gov/study/NCT07442006","untrusted":true}},{"nct_id":"NCT04670666","title":{"text":"Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"EMS","untrusted":true},"status":"RECRUITING","last_update_posted":"2025-12-08","start_date":"2024-11-18","link":{"text":"https://clinicaltrials.gov/study/NCT04670666","untrusted":true}},{"nct_id":"NCT07019012","title":{"text":"Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.","untrusted":true},"phase":["PHASE4"],"sponsor":{"text":"Huazhong University of Science and Technology","untrusted":true},"status":"RECRUITING","last_update_posted":"2025-06-13","start_date":"2025-07-30","link":{"text":"https://clinicaltrials.gov/study/NCT07019012","untrusted":true}},{"nct_id":"NCT06095492","title":{"text":"Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus","untrusted":true},"phase":["NA"],"sponsor":{"text":"Medanta, The Medicity, India","untrusted":true},"status":"RECRUITING","last_update_posted":"2024-12-05","start_date":"2023-10-30","link":{"text":"https://clinicaltrials.gov/study/NCT06095492","untrusted":true}}],"fact_id":"602880f8078a0b44009e6d5f"}]},"assistance_and_offers":{"programs_listing_this_drug":[{"name":{"text":"Teva Cares Foundation","untrusted":true},"type":"manufacturer","url":"https://www.tevacares.org/","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Viatris (Mylan) Patient Assistance","untrusted":true},"type":"manufacturer","url":"https://www.viatris.com/en-us/lm/united-states/patient-assistance-program","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Walmart $4 Prescriptions","untrusted":true},"type":"discount","url":"https://www.walmart.com/cp/4-dollar-prescriptions/1078664","status":null,"needs_status_check":false,"has_offer":false},{"name":{"text":"Mark Cuban Cost Plus Drugs","untrusted":true},"type":"discount","url":"https://costplusdrugs.com/","status":null,"needs_status_check":false,"has_offer":false}],"manufacturer_offers":[],"note":"A program that lists a drug has not decided anything about any person: each program decides who qualifies, and a status other than open means it may not take new patients. Offers change and expire; read each offer's source and stated end date. A price figure is what the page states, not a quote."},"spending":{"reported_under":{"generic":{"text":"Empaglifloz/Linaglip/Metformin","untrusted":true},"brand":{"text":"Trijardy XR","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":1450471.66,"claims":1851,"beneficiaries":983,"average_spending_per_claim_usd":783.61515937,"fact_id":"78c8edcc1fbe77db93c4df39"},{"year":2021,"gross_spending_usd":17542709.55,"claims":21307,"beneficiaries":5734,"average_spending_per_claim_usd":823.33080912,"fact_id":"019227176edb2d3c62416236"},{"year":2022,"gross_spending_usd":43294714.48,"claims":49034,"beneficiaries":11238,"average_spending_per_claim_usd":882.95294041,"fact_id":"c5d11c7d9d010b74ef58962a"},{"year":2023,"gross_spending_usd":76136040.44,"claims":80529,"beneficiaries":16941,"average_spending_per_claim_usd":945.4487258,"fact_id":"d6e451545d93f18d95f30e82"},{"year":2024,"gross_spending_usd":99142501.43,"claims":112533,"beneficiaries":21512,"average_spending_per_claim_usd":881.00825029,"fact_id":"4aa39596a575af3e32b9e082"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"empagliflozin","untrusted":true},"designation_count":1,"approved_count":0,"recent":[{"designated":"2026-11-02","use":{"text":"treatment of glycogen storage disease type 1b (GSD1b)","untrusted":true},"status":"Designated","sponsor":{"text":"Vitalis Scientia LLC","untrusted":true},"approved":false}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"2bdcac1644e899b98d840283"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":5,"all_states_medicaid_reimbursed_usd":437347.04,"all_states_medicaid_paid_prescriptions":533,"top_states":[{"state":"NY","medicaid_paid_prescriptions":195,"medicaid_reimbursed_usd":232395.96,"total_reimbursed_usd":232395.96,"packages":2,"covers":"all_record_types","fact_id":"cf93b0a06438fbe1117e044a"},{"state":"OK","medicaid_paid_prescriptions":139,"medicaid_reimbursed_usd":80244.8,"total_reimbursed_usd":83902.61,"packages":1,"covers":"fee_for_service_only","fact_id":"c7ae3408a06ec312a528925f"},{"state":"TX","medicaid_paid_prescriptions":74,"medicaid_reimbursed_usd":66800.76,"total_reimbursed_usd":66800.76,"packages":1,"covers":"all_record_types","fact_id":"648e6277c133e0cc3e86be36"},{"state":"OR","medicaid_paid_prescriptions":70,"medicaid_reimbursed_usd":29169.93,"total_reimbursed_usd":29169.93,"packages":1,"covers":"all_record_types","fact_id":"660aae799240594ea725d4df"},{"state":"FL","medicaid_paid_prescriptions":55,"medicaid_reimbursed_usd":28735.59,"total_reimbursed_usd":28735.59,"packages":1,"covers":"all_record_types","fact_id":"5227c3d64aa74777a648398b"}],"unlabelled_state_code_xx":null,"built_from_facts":6,"facts_fee_for_service_only":1,"older_year_facts_not_used":41,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"a1ed7cd2298be0f1c973fdf8","field":"ndc.listing","entity":"ndc:00597038013"},{"fact_id":"f2ef3c4be8a6a8535c07260c","field":"ndc.listing","entity":"ndc:00597038068"},{"fact_id":"242780658b5db194c9c65710","field":"ndc.listing","entity":"ndc:00597038577"},{"fact_id":"df2664c78e85402d3067a344","field":"drug.generic_entry_earliest","entity":"application:NDA212614"},{"fact_id":"bc41267d6c71d48ad803c9de","field":"drug.patent","entity":"application:NDA212614"},{"fact_id":"3720c00e60bc9c26b58eaf11","field":"drug.label_event","entity":"application:NDA212614"},{"fact_id":"685c5613372d4fce96e1f914","field":"drug.label_event","entity":"application:NDA212614"},{"fact_id":"977072eec3870c3e6925365f","field":"drug.label_event","entity":"application:NDA212614"},{"fact_id":"603a1defbc3ae9ba6435466d","field":"drug.label_event","entity":"application:NDA212614"},{"fact_id":"0d9a6c7f8a7d290b64ba2cac","field":"drug.label_event","entity":"application:NDA212614"},{"fact_id":"c8cc21003e133b92c95ca04b","field":"drug.marketing_status","entity":"application:NDA212614"},{"fact_id":"2bfab213444f65df9c975e42","field":"drug.marketing_status","entity":"application:NDA212614"},{"fact_id":"2b8c1bf32387b67f20949780","field":"drug.marketing_status","entity":"application:NDA212614"},{"fact_id":"18025dd8a04b3cbf213d2788","field":"drug.marketing_status","entity":"application:NDA212614"},{"fact_id":"ab0e426b6d1a73f39080ec45","field":"drug.trial_access","entity":"drug:empagliflozin"},{"fact_id":"602880f8078a0b44009e6d5f","field":"drug.trial_access","entity":"drug:linagliptin"},{"fact_id":"78c8edcc1fbe77db93c4df39","field":"drug.partd_spending","entity":"drug:empaglifloz-linaglip-metformin|trijardy-xr"},{"fact_id":"019227176edb2d3c62416236","field":"drug.partd_spending","entity":"drug:empaglifloz-linaglip-metformin|trijardy-xr"},{"fact_id":"c5d11c7d9d010b74ef58962a","field":"drug.partd_spending","entity":"drug:empaglifloz-linaglip-metformin|trijardy-xr"},{"fact_id":"d6e451545d93f18d95f30e82","field":"drug.partd_spending","entity":"drug:empaglifloz-linaglip-metformin|trijardy-xr"},{"fact_id":"4aa39596a575af3e32b9e082","field":"drug.partd_spending","entity":"drug:empaglifloz-linaglip-metformin|trijardy-xr"},{"fact_id":"2bdcac1644e899b98d840283","field":"drug.orphan_designation","entity":"drug:empagliflozin"},{"fact_id":"cf93b0a06438fbe1117e044a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597039013:NY"},{"fact_id":"c7ae3408a06ec312a528925f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597038577:OK"},{"fact_id":"648e6277c133e0cc3e86be36","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597038013:TX"},{"fact_id":"660aae799240594ea725d4df","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597039582:OR"},{"fact_id":"5227c3d64aa74777a648398b","field":"ndc.medicaid_state_utilization","entity":"ndc_state:00597038577:FL"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}